Moreover, emerging evidence suggests that GLP-1 receptor agonists are not only effective in preventing the accumulation of amyloid beta, a protein commonly associated with Alzheimer’s disease, but also in mitigating the hyperphosphorylation and aggregation of another critical protein in the disease’s progression: tau. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.